Current clinical trial development for KMT2A-rearranged infant ALL will therefore focus on integration of novel agents which have strong preclinical data, such as venetoclax (25) and menin inhibitors (26), and immunotherapeutic approaches with promising preliminary clinical findings, such as blinatumomab (27) and CAR T-cell therapy (28). The gene discussed is MEN1; the disease is acute lymphoblastic leukemia.